CO32 | Treatment with teriparatide on primary and glucocorticoid-induced osteoporosis

Background: Teriparatide is an osteoporosis treatment that significantly increases the Bone Mineral Density (BMD) in the lumbar and femoral areas and decreases the incidence of new fractures due to its anabolic action.Methods: This trial evaluates the effectiveness of teriparatide in preventing new vertebral and femoral fractures in patients with osteoporosis. The patients studied were divided into two groups (G1 and G2). In G1 30 females between 55-72 years with post-menopausal osteoporosis, in G2 20 females between 45-52 years with GIO. BMD was measured by DEXA before and after 18 months of treatment at lumbar spine (LS) (L1-L4) and femoral neck (FN). The results are reported in g/cm². Statistical analysis was performed using Student’s t-test and data reported as mean±standard deviation.Results: In G1 basal BMD values were 0.66±1.25 in LS and 0.64±0.11 g/cm² in FN. After treatment BMD values were 0.74±1.11 g/cm² in LS and 0.67±0.09 g/cm2 in FN. In G2 basal BMD values were 0.68±0.09 in LS and 0.66±0.13 g/cm² in FN. After treatment, BMD values were 0.74±0.10 g/cm² in LS and 0.68±0.12 g/cm² in FN. Basal BMD values increase significantly in both groups.Conclusions: The data confirm effectiveness of teriparatide increasing lumbar and femoral BMD values on primary and glucocorticoid-induced osteoporosis. During the observation period there were not new fractures. The data also demonstrate that teriparatide prevents the development of new fractures in both forms of osteoporosis.